Who is sponsoring NCT05810142?

NCT05810142 is sponsored by RenJi Hospital.

What drugs are being tested in NCT05810142?

Interventions in NCT05810142: furquimatinib and sintilimab.

What condition does NCT05810142 study?

NCT05810142 studies Third-line Treatment, Dvanced Duodenal Adenocarcinoma, Furquinelone Combined With Sintilimab.

Is NCT05810142 still recruiting?

NCT05810142 is currently not yet recruiting. Last updated 12 April 2023.

Last reviewed 2023-04-12 · How we verify

NCT05810142

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab

Not yet recruiting Last updated 12 April 2023

What this trial tests

trial testing furquimatinib and sintilimab in Third-line Treatment in 20 participants. Not yet recruiting.

Timeline

1 July 2023

Primary endpoint
31 December 2025

31 December 2026

Quick facts

Lead sponsor	RenJi Hospital
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	20
Start date	1 July 2023
Primary completion	31 December 2025
Estimated completion	31 December 2026

Drugs / interventions tested

furquimatinib and sintilimab — full drug profile →

Conditions studied

Third-line Treatment — all drugs for Third-line Treatment →
Dvanced Duodenal Adenocarcinoma — all drugs for Dvanced Duodenal Adenocarcinoma →
Furquinelone Combined With Sintilimab — all drugs for Furquinelone Combined With Sintilimab →

Sponsor

RenJi Hospital

Who can join

Adults 18 to 75, any sex, with Third-line Treatment or Dvanced Duodenal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research project is a single-center, retrospective clinical exploration study. It aims to retrospectively analyze data from 20 patients with advanced duodenal adenocarcinoma who received third-line treatment with furquinelone combined with sintilimab, in order to determine the clinical efficacy and safety of this combination therapy in advanced duodenal cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other RenJi Hospital trials

Trials by the same sponsor.

NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05810142 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
Last refreshed: 12 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05810142.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing